恢复期血浆疗法

预约门诊
打印

妙佑医疗国际的方法

协作

多年来，妙佑医疗国际一直在研究使用恢复期血浆的方法，并已将其用于治疗传染病。通过临床试验，研究人员收集了数据并制定了救生程序。

妙佑医疗国际与美国各地的医疗中心合作，从已经康复的 2019 冠状病毒病患者收集血浆，用于康复治疗。妙佑医疗国际协调了这项政府资助的项目。

团队方式

妙佑医疗国际的医生团队来自多个领域，这些领域包括传染病、实验室医学和病理学、血液采集和检测（输血医学）、药剂学、病毒研究（病毒学）和心血管疾病，这些医生共同研究 2019 冠状病毒病的潜在治疗方案，如恢复期血浆治疗。

研究

妙佑医疗国际的研究人员正在研究导致 COVID-19 的病毒及其对免疫系统的影响。他们也在研究2019 冠状病毒病药物和治疗方法，包括康复者恢复期血浆。

此外，研究人员还致力于开展诊断和抗体检测，并向医疗中心通报预防和控制感染的方法。研究人员积极参与 COVID-19 和其他传染病的临床试验。

来自妙佑医疗国际员工
申请预约
医生与科室
April 28, 2021
打印
  1. Convalescent plasma COVID-19: EUA letter of authorization. U.S. Food and Drug Administration. https://www.fda.gov/media/141477/download. Accessed April 22, 2021.
  2. Joyner MJ, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three month experience. Preprint. medRxiv. 2020; doi:10.1101/2020.08.12.20169359.
  3. FDA issues emergency use authorization for convalescent plasma as potential promising COVID–19 treatment. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Accessed Aug. 24, 2020.
  4. Host modifiers and immune-based therapy under evaluation for treatment of COVID-19. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/. Accessed May 8, 2020.
  5. Donate COVID-19 plasma. U.S. Food and Drug Administration. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma. Accessed Aug. 24, 2020.
  6. Plasma donations from recovered COVID-19 patients. American Red Cross. https://www.redcrossblood.org/donate-blood/dlp/plasma-donations-from-recovered-covid-19-patients.html. Accessed May 8, 2020.
  7. Rajendran K, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Journal of Medical Virology. 2020; doi:10.1002/jmv.25961.
  8. Investigational COVID-19 convalescent plasma — Emergency INDs: Frequently asked questions. U.S. Food and Drug Administration. https://www.fda.gov/media/136470/download. Accessed May 8, 2020.
  9. Expanded access to convalescent plasma for the treatment of patients with COVID-19. https://www.uscovidplasma.org/. Accessed Aug. 24, 2020.
  10. Coronavirus disease 2019 (COVID-2019). Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed May 8, 2020.
  11. Kim AR. Coronavirus disease 2019 (COVID-19): Management in hospitalized adults. https://www.uptodate.com/contents/search. Accessed May 8, 2020.
  12. AskMayoExpert. COVID-19: Adult. Mayo Clinic; 2020.
  13. Joyner MJ (expert opinion). Mayo Clinic. May 8, 2020.
  14. Emergency use authorization. U.S. Food and Drug Administration. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. . Accessed April 22, 2021.
  15. Coronavirus disease 2019 (COVID-19) treatment guidelines: Convalescent plasma. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/convalescent-plasma/. Accessed April 22, 2021.
  16. Klassen SA, et al. The effect of convalescent plasma therapy on COVID-19 patient mortality: Systematic review and meta-analysis. Mayo Clinic Proceedings. 2021; doi:10.1016/j.mayocp.2021.02.008.
  17. Joyner MJ, et al. Convalescent plasma antibody levels and risk of death from COVID-19. The New England Journal of Medicine. 2021; doi:10.1056/NEJMoa2031893.

相关

恢复期血浆疗法